

FOI 2211

27/02/2024

FREEDOM OF INFORMATION ACT 2000 – INFORMATION REQUEST

Q1 – How many patients were treated with the following drugs for the following diseases from the start of Oct 2023 to the end of Dec 2023?

Please use the latest available 3 months if October to December is not available and specify which 3 months has been used. Please ignore any cells which have been blanked out.

Drug Name	Plaque psoriasis	Crohn's Disease	Ulcerative colitis	Psoriatic arthritis	Ankylosing spondylitis (inc. axial spondylitis)	Rheumatoid arthritis
Adalimumab (Humira)	11	8	0	14	15	4
Adalimumab (Biosimilars)	218	120	61	177	145	155
Apremilast	0			0		
Bimekizumab	2					
Brodalumab	8					
Certolizumab Pegol	8			25	27	20
Deucravacitinib	0					
Etanercept (Enbrel)	1			4	0	6
Etanercept (Biosimilars)	2			63	33	99
Guselkumab	65			6		
Infliximab (Remicade)	0	0	0	0	0	0



Southern Health and Social Care Trust

Infliximab (Biosimilars)	3	39	49	7	8	8
Ixekizumab	95			37	12	
Risankizumab	63	0		1		
Secukinumab	0			80	53	
Tildrakizumab	9					
Ustekinumab	27	75	35	0		
Upadacitinib		1	3	2	2	13
Vedolizumab		40	55			
Filgotinib			0			0
Golimumab			1	26	36	20
Mirikizumab			0			
Ozanimod			0			
Tofacitinib			5	5	0	7
Abatacept						97
Baricitinib						52
Rituximab						86
Sarilumab						16
Tocilizumab						28

Email: Foi.Team@Southerntrust.hscni.net